jobs.jnj.com/en/jobs/

✕

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.

Share

More HIV News

Innovation

March 29, 2022

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
Innovation

March 24, 2022

U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
Innovation

February 01, 2022

U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
Innovation

December 01, 2021

This Ring May Just Help Protect Women Against HIV
Our Company

December 01, 2021

World AIDS Day 2021: How Far We’ve Come, and Yet to Go
Innovation

November 30, 2021

How MenStar's MINA Campaign is Meeting the Needs of Men in the HIV Epidemic
Our Company

August 31, 2021

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Innovation

July 26, 2021

The Sky’s the Limit: Drones Delivering HIV Supplies in Remote Uganda
Innovation

July 22, 2021

How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
Personal Stories

July 19, 2021

"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
Our Company

July 15, 2021

How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
Innovation

June 01, 2021

How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
Our Company

March 06, 2021

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
Innovation

January 21, 2021

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
Innovation

December 21, 2020

Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe
Innovation

October 16, 2020

Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
Innovation

March 20, 2020

Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
Innovation

March 11, 2020

Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months
Our Company

October 04, 2019

Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Innovation

September 04, 2019

Johnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to Zimbabwe
Innovation

July 23, 2019

Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen

Circular image

We’re Committed to Helping Lead the Fight Against HIV/AIDS

We’re Committed to Helping Lead the Fight Against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

Learn more